Last $11.56 USD
Change Today +0.01 / 0.09%
Volume 1.3M
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014

Momenta Pharmaceuticals Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: Mar-25-2014, Rick Shea. Mar-26-2014, Rick Shea.

Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Momenta Pharmaceuticals Inc. reported earnings results for the fourth quarter and full year ended December 31, 2013. The company has reported that net loss for the fourth quarter ended December 31, 2013 was $30.06 million, or $0.59 loss per share, compared to a net loss of $17.68 million, or $0.35 loss per share, for the same quarter ended December 31, 2012. Total collaboration revenue for the fourth quarter ended December 31, 2013 was $12.75 million, compared to $12.73 million for the same quarter ended December 31, 2012. Net loss for the year ended December 31, 2013 was $108.41 million, or $2.13 loss per share, compared to a net loss of $58.65 million, or $1.16 loss per share, for the year ended December 31, 2012. Total collaboration revenue for the year ended December 31, 2013 was $35.46 million, compared to $63.92 million for the year ended December 31, 2012.

Momenta Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

Momenta Pharmaceuticals Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net loss of $30,062,000 or $0.59 per share basic and diluted compared to $17,677,000 or $0.35 per share a year ago. Total collaboration revenue was $12,750,000 compared to $12,728,000 a year ago. Operating loss was $30,336,000 against $18,185,000 a year ago. For the year, the company reported net loss of $108,408,000 or $2.13 per share basic and diluted compared to $58,648,000 or $1.16 per share a year ago. Total collaboration revenue was $35,465,000 compared to $63,921,000 a year ago. Operating loss was $109,591,000 against $60,106,000 a year ago. For the year 2014, the company expects its total operating expenses, excluding stock-based compensation and net of collaborative revenues, are expected to average $30 to $32 million per quarter. The company expects net cash usage, excluding revenue from the potential launch of M356, will average approximately $30 million per quarter, with quarterly cash burn in the second half of 2014 partially offset by an expected $19 million from milestone payments earned under the Baxter collaboration.

Momenta Pharmaceuticals Inc. Presents at 9th Annual Summit on Biosimilars, Mar-19-2014 through Mar-20-2014

Momenta Pharmaceuticals Inc. Presents at 9th Annual Summit on Biosimilars, Mar-19-2014 through Mar-20-2014. Venue: Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Mar-19-2014, Bruce A. Leicher, Senior Vice President, General Counsel and Corporate Secretary. Mar-20-2014, Barbara Rosengren, Vice President, Strategic Program Development, Bruce A. Leicher, Senior Vice President, General Counsel and Corporate Secretary.

Momenta Pharmaceuticals Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-12-2014 03:55 PM

Momenta Pharmaceuticals Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-12-2014 03:55 PM. Venue: The Waldorf Astoria Hotel, New York, New York, United States. Speakers: Richard P. Shea, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $11.56 USD +0.01

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eagle Pharmaceuticals Inc/DE $12.35 USD +0.35
Natco Pharma Ltd 714.65 INR +7.95
OraSure Technologies Inc $6.67 USD +0.23
ProPhase Labs Inc $1.87 USD +0.0536
Sucampo Pharmaceuticals Inc $6.96 USD +0.135
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.7x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.